Small molecule-based PD-1 pathway blockade for Human cancer therapy: DEAR1/TRIM62 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 29/october/2016, 11. 30 am

Natural product therapy for brain repair and Life-span extension: Ursolic acid, found in Tulsi and apple peels, among others, increases VGF and BDNF expression, promotes Oligodendrocytes (OP) proliferation, triggers myelination on neurons, reverts neural damage, produces anti-depressant like effects, and prolongs lifespan via up-regulation of its target gene, 28/October/2016, 9.29 pm
October 28, 2016
Molecular therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: BMP2 promotes an insulin-sensitized state via up-regulation of reprogramming protein Lin28, 29/October/2016, 11.11 am
October 29, 2016
Show all

Introduction:What they say:

A recent study from Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, United States shows that “TGF-β1-Mediated Smad3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.” This study was published in the 28 September 2016 issue of Cancer Discovery (one of the best journals in Cancer Science with an impact factor of 19+) by Prof Andrea L. Cox, Park BV and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based PD-1 pathway blockade for Human cancer therapy: DEAR1/TRIM62 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year recently.


What we say: Research Findings

This suggests that DEAR1/TRIM62, by decreasing the expression of its target gene, it may suppress the expression of PD-1. Thereby, it may (1) increase the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes; (2) augment antitumor activity of the immune system; & (3) inhibit metastatic cancer progression. Thus, pharmacological formulations encompassing “DEAR1/TRIM62 activators” may be used to inhibit the progression of tumors.


Idea Proposed/Formulated (with factual evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Small molecule-based PD-1 pathway blockade for Human cancer therapy: DEAR1/TRIM62 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 29/october/2016, 11. 30 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation


Amount: $300

Undisclosed information: How DEAR1/TRIM62 suppresses the expression of PD-1 and augments anti-tumor immunity

satisfaction-guarantee

Results guaranteed if not refunded

Comments are closed.